Table 1.
Characteristics and treatment receipt of Stage III Colon Cancer Patients in SEER-Medicare Study Population by Time Period (N=2800)
| Characteristic (N=2800) | May 2003–Apr 2004 | May 2004–Apr 2005 | May 2005–Apr 2006 |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Treatment:* | |||
| 5-FU without oxaliplatin | 1028 (92.3) | 609 (64.3) | 353 (47.8) |
| Oxaliplatin | 86 (7.7) | 338 (35.7) | 386 (52.2) |
| Race: | |||
| Caucasian American | 975 (87.7) | 832 (87.9) | 639 (86.6) |
| African American | 83 (7.5) | 60 (6.3) | 53 (7.2) |
| Other | 54 (4.9) | 54 (5.7) | 46 (6.2) |
| Age: | |||
| Mean (sd) | 75.1 (5.5) | 74.5 (5.6) | 74.8 (5.6) |
| Sex: | |||
| Female | 602 (54.0) | 517 (54.6) | 419 (56.7) |
| Male | 512 (46.0) | 430 (45.4) | 320 (43.3) |
| Urbanity: | |||
| Metro | 931 (83.6) | 781 (82.5) | 616 (83.4) |
| Urban | 166 (14.9) | 146 (15.4) | 108 (14.6) |
| Rural | 17 (1.5) | 20 (2.1) | 15 (2.0) |
| Substage: | |||
| A | 99 (8.9) | 115 (12.1) | 80 (10.8) |
| B | 662 (59.8) | 542 (57.2) | 412 (55.8) |
| C | 346 (31.3) | 290 (30.6) | 247 (33.4) |
| Grade: | |||
| Differentiated | 749 (67.2) | 635 (67.1) | 490 (66.3) |
| Undifferentiated/Unk | 365 (32.8) | 312 (32.9) | 249 (33.7) |
| Census Median Income:** | |||
| Mean (sd) | 49.8 (22.3) | 50.5 (24.2) | 50.6 (23.6) |
| Congestive heart failure (CHF): | 37 (3.3) | 42 (4.4) | 30 (4.1) |
| Myocardial Infarction (MI): | 32 (2.9) | 21 (2.2) | 15 (2.0) |
| Chronic obstructive pulmonary disease: | 66 (5.9) | 60 (6.3) | 43 (5.8) |
| Cerebrovascular Disease (CVD): | 31 (2.8) | 17 (1.8) | 16 (2.2) |
| Diabetes: | 96 (8.6) | 98 (10.3) | 115 (15.6) |
| Peripheral Vascular Disease (PVD): | 29 (2.6) | 24 (2.5) | 17 (2.3) |
Abbreviations SD, standard deviation; SEER, Surveillance, Epidemiology, and End Results.
Peptic ulcer disease, mild liver disease, paraplegia/hemiplegia, chronic renal failure, and rheumatologic disease are not shown but were also included in propensity score.
*
First chemotherapy treatment received by newly diagnosed patients (intent-to-treat)
**
USD, thousands